Biogen (BIIB) and Eisai said Friday that an analysis of real-world data showed that most patients choose to continue receiving lecanemab after the initial 18 months of treatment.

The companies said 94% of patients who completed 18 months of lecanemab treatment in a phase 3 study enrolled in the subsequent long-term extension study.

In the extension study, patients continue to benefit from four years of lecanemab treatment, showing a reduction in cognitive decline, compared with the natural course of Alzheimer's disease, according to a statement.

Price: 182.62, Change: -0.81, Percent Change: -0.44